Becton Dickinson
BDX

$237.30

1.94%

Market Cap: 68.6B

About: Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Employees: 73,000

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

0

News positive %

of 15 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% less funds holding

Funds holding: 1,546 [Q4 2023] → 1,542 (-4) [Q1 2024]

1% less capital invested

Capital invested by funds: $61.2B [Q4 2023] → $60.4B (-$884M) [Q1 2024]

3% less first-time investments, than exits

New positions opened: 141 | Existing positions closed: 145

6% less repeat investments, than reductions

Existing positions increased: 566 | Existing positions reduced: 600

15% less call options, than puts

Call options by funds: $187M | Put options by funds: $219M

33.95% less ownership

Funds ownership: 118.39% [Q4 2023] → 84.45% (-33.95%) [Q1 2024]

39% less funds holding in top 10

Funds holding in top 10: 18 [Q4 2023] → 11 (-7) [Q1 2024]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$255

7%

upside

Avg. target

$285

20%

upside

High target

$312

31%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Stifel Rick Wise	18%upside $280	Buy Maintained	26 Jul 2024
Citigroup Joanna Wiensch	7%upside $255	Neutral Maintained	10 Jul 2024
Evercore ISI Group Vijay Kumar	20%upside $285	Outperform Maintained	2 Jul 2024
Goldman Sachs David Roman	15%upside $274	Buy Initiated	30 May 2024
Barclays Travis Steed	31%upside $312	Overweight Maintained	6 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 15 articles about BDX published over the past 30 days

BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J.

BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases

BD Board Declares Dividend

FRANKLIN LAKES, N.J. , July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024.

BD Board Declares Dividend

Zacks Investment Research

What Makes Becton Dickinson (BDX) a New Buy Stock

Becton Dickinson (BDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Becton Dickinson (BDX) a New Buy Stock

Zacks Investment Research

BDX vs. MMSI: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?

BDX vs. MMSI: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage

BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.

BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage

3 Healthcare Stocks to Buy Now to Profit From Aging Population Trends

If you can count, you may find healthcare stocks focused on the aging population to be a compelling opportunity. What do I mean?

3 Healthcare Stocks to Buy Now to Profit From Aging Population Trends

Becton Dickinson's stock bounces as FDA addresses supply issue with blood-culture vials

Medical-supply company looks to fill gaps as former supplier restarts production of vials.

Becton Dickinson's stock bounces as FDA addresses supply issue with blood-culture vials

US FDA flags shortage of Becton Dickinson's blood test tubes

The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' blood test tubes used in diagnosing bacterial and fungal infections.

US FDA flags shortage of Becton Dickinson's blood test tubes

BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials

Company Committed to Support Global Health and Customers BD Taking all Available Measures to Mitigate Supplier Issue FRANKLIN LAKES, N.J. , July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S. FDA letter to health care providers regarding the supply of blood culture vials: Nikos Pavlidis, worldwide president of BD Diagnostic Solutions said, "BD is experiencing reduced availability of blood culture vials from our supplier.

BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials

BD Surpasses Scope 1 and 2 Reduction Milestones for FY 2023

FRANKLIN LAKES, N.J. , July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1].

BD Surpasses Scope 1 and 2 Reduction Milestones for FY 2023

See News Rankings